Bone Drugs Proven to Cause Poor Bone Quality in Humans

Two studies from the Special Surgery (HHS) andIn a second unrelated prospective pilot study,
Columbia University Medical Center have confirmedconducted at HSS and funded in part by the NIH,
the recent media attention on the extreme dangersresearchers evaluated the bone composition of 21
to bone from the long-term use of bone drugspost-menopausal women who were treated for
(bisphosphonates). The researchers found that afterfemoral fractures. Of these, 12 patients had a history
four years of use bisphosphonates had a negativeof bisphosphonate treatment for an average of 8.5
effect on bones causing declining structural integrityyears, while nine had not had bisphosphonate
of bone. This finding is very important becausetreatment.
doctors expect patients to take these drugs for life.Samples of bone were removed from each patient's
ABC news recently highlighted a number of faithfulfemur during surgical placement of a femoral nail. Both
Fosamax users who experienced abnormal fracturesmicro-architecture and material properties of the
in their large femur bone from doing very little.bone were analyzed.
In the new study researchers at Columbia evaluatedThe study found that, although there were no
the bone structure of 111 postmenopausal womendifferences in bone micro-architecture between
with primary osteoporosis, 61 of whom had beengroups, the material properties of bone in
taking bisphosphonates for a minimum of four yearsbisphosphonate-treated patients displayed reduced
and 50 controls taking calcium and vitamin Dbone tissue heterogeneity, which may be associated
supplements. This type of analysis of bone sampleswith reduced strength and potentially may contribute
from humans has not been done before. It confirmsto the presentation of atypical fractures.
earlier animal experiments with these drugs that"Patients who had been treated with
show the higher the dose the more deleterious thebisphosphonates showed a reduction in tissue
adverse effect on bone integrity.heterogeneity, specifically with mineral content and
"Recent research suggests that suppressed bonecrystal size compared with the control group,"
remodeling from long-term bisphosphonate use mightGladnick said.
result in brittle bone that is prone to atypical"This tells us that there may be some measurable
fractures," said lead author Brian Gladnick. While theredifferences in bone quality parameters in patients on
is recent research these basic facts have beenlong-term bisphosphonate therapy, which might
known for a long time. Bone drugs interfere withcontribute to the development of atypical fractures."
normal bone regeneration, leaving older bone in place.Bone drugs are poisons to bone. Only the most inept
I have pointed out for many years that this cannotsystem of medicine could dream of giving them to
possibly help bone quality as someone grows older.relatively healthy people for long-term use in the
Yet, doctors continue to use these drugs on theirname of prevention. This is a major betrayal of the
unsuspecting patients even though the science haspublic trust.
been perfectly clear for over a decade.